Outpatient laser treatment for repeat low-grade bladder tumors
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an outpatient laser procedure to remove recurring low-grade, non-solid bladder tumors. It may help prevent or control tumor growth with treatment done outside the hospital, if you meet the tumor and health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have at least one bladder tumor bigger than 1 cm
- Tumors should be papillary or non-solid (not solid-looking)
- You have had previous low-grade, non-muscle-invasive bladder cancer
- Your tumor should be 3 cm or smaller
- You must be able to read and understand the study information and consent in the listed languages and sign the consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a chemotherapy drug placed directly into the bladder (chemoablation) works as well as surgery followed by chemotherapy for people whose low-grade bladder tumors have come back. It aims to find a less invasive option that still controls the cancer.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
This study tests a new way to give a chemotherapy drug during bladder surgery to help stop the cancer from returning. It is for people with a type of bladder cancer that has not spread into the muscle.
This study tests a more targeted way to treat low-grade bladder cancer using chemotherapy placed directly into the bladder. Before treatment, your cancer cells are grown in the lab to see which drug works best for you.
This trial tests radiotherapy (high-energy X-rays) for a specific type of early-stage bladder cancer (CIS) that hasn't gone away after BCG treatment. It's for people who can't or choose not to have bladder removal surgery.
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.